{'fraction_non_alphanumeric': 0.018823529411764704, 'fraction_numerical': 0.00823529411764706, 'mean_word_length': 5.122302158273381, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Monocyclic and Fused Azines and Azoles as Histamine H4 Receptor Ligands.

The histamine H4 receptor has stood out since its discovery and identification in 2000 as an important target in the search for potential new drugs for the treatment of inflammatory and allergic diseases such as rhinitis, pruritus and asthma. Thus, in the last decade, both industry and academia have performed an intensive and productive search for new ligands of this newest subtype of histamine receptor. The most promising compounds found include monocyclic and fused azines, and azoles such as bispyrimidines, di- and triaminopyrimidines, quinazolines, imidazoles, indoles, benzimidazoles and benzazoles. The aim of this review is to give an insight into the current state of the art in the field of histamine H4 receptor research, focusing mainly on the last five years.